Results 111 to 120 of about 29,271 (207)

Single Cell RNA Transcriptomics of Mantle Cell Lymphoma Reveals the Presence of Treatment‐Resistant Subclones at the Time of Diagnosis

American Journal of Hematology, Volume 101, Issue 5, Page 1025-1035, May 2026.
ABSTRACT Mantle cell lymphoma (MCL) is a B‐cell malignancy with a chronically relapsing clinical course and pronounced genetic heterogeneity. To investigate the clonal dynamics underlying early disease relapse, we performed single‐cell RNA sequencing of paired tumor samples collected at diagnosis and at first relapse. Inference of copy number variants (
Dmitry Manakov, Magdalena Klanova, Michal Kolar, Robert Ivanek, Florian Geier, Julien Roux, Tomas Zikmund, Lucie Winkowska, Eva Kriegova, Jirina Manakova, Liliana Tuskova, Silvia Spanikova, Alexandra Scasna, Marek Trneny, Pavel Klener   +14 more
wiley   +1 more source

Adverse Prognostic Significance of Activation‐Induced Cytidine Deaminase in Diffuse Large B‐Cell Lymphoma Patients Treated With R‐CHOP

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background A number of studies have demonstrated the important role of activation‐induced cytidine deaminase (AID) in the pathogenesis of diffuse large B‐cell lymphoma (DLBCL). AID has been relatively underexplored as a prognostic factor in DLBCL, and its role remains controversial.
Mardiah Suci Hardianti, Nungki Anggorowati, Syahru Agung Setiawan, Miraz Radhea Bagaskoro, Johan Kurnianda, Kartika Widayati Taroeno‐Hariadi, Ibnu Purwanto, Susanna Hilda Hutajulu   +7 more
wiley   +1 more source

Outcomes and salvage strategies for large B‐cell lymphoma progressing after second‐line CAR T‐cell therapy: A DESCAR‐T study from the LYSA group

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Relapse after chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL) is associated with a dismal prognosis. Although Phase 3 trials have established CAR T‐cells as standard second‐line (2L) therapy, outcomes and optimal management after relapse in this setting remain unknown because no real‐world data are currently ...
Pierre Sesques, Guillaume Manson, Guillaume Cartron, François‐Xavier Gros, Franck Morschhauser, Cristina Castilla‐Llorente, Gabriel Brisou, Pierre Bories, Catherine Thieblemont, Laurianne Drieu La Rochelle, Benoit Tessoulin, Axel André, Cedric Rossi, Jérôme Paillassa, Stephanie Guidez, Antoine Capes, Laura Herbreteau, Sylvain Choquet, Jacques‐Olivier Bay, Adrien Chauchet, Laure Lebras, Fabien Claves, Julie Abraham, Jean‐Valère Malfuson, Marie‐Thérèse Rubio, Justine Decroocq, Luc‐Matthieu Fornecker, Gandhi Damaj, Ludovic Fouillet, Magalie Joris, Michael Loschi, Olivier Hermine, Hadia Hafirassou, Emelie Van Zele, Vivien Dupont, Steven Le Gouill, Roch Houot, Vincent Camus   +37 more
wiley   +1 more source

CAR‐T Cells: Current Status, Challenges, and Future Prospects

MedComm, Volume 7, Issue 5, May 2026.
This graphical abstract outlines the current status, challenges, and future prospects of CAR‐T cells. The biological basis of CAR‐T cell therapy is the elegant redirection of adaptive immunity. Its initial successes have exposed a landscape of multifaceted challenges.
Aya Sedky Adly, Guillaume Cartron, Afnan Sedky Adly, Jean‐Christophe Egea, Pierre‐Yves Collart Dutilleul, Mahmoud Sedky Adly, Martin Villalba   +6 more
wiley   +1 more source

Population Pharmacokinetic Modeling and Exposure‐Response Analyses of Nemtabrutinib in Patients With Hematologic Malignancies

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 5, May 2026.
ABSTRACT Nemtabrutinib is a Bruton's tyrosine kinase (BTK) inhibitor under clinical investigation in patients with hematologic malignancies, including chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL). Nemtabrutinib plasma concentration data from 578 patients enrolled in phase 1 and 2 clinical studies, treated with doses from 5 to ...
Chiara C. Kemal, Thijs J. Zweers, Elke H. J. Krekels, Manash S. Chatterjee   +3 more
wiley   +1 more source

Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US

The Journal of Dermatology, Volume 53, Issue 5, Page 758-773, May 2026.
ABSTRACT Vitiligo is a chronic autoimmune depigmenting disease characterized by loss of pigment in the skin, hair, or both. As treatment options evolve, particularly with the emergence of oral Janus kinase inhibitors and dual Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor, it is essential to assess ...
Kennedy Cook, Nada M. Elbuluk, Roni Adiri, Alexandre Lejeune, Thomas Edwards, Milena A. Gianfrancesco, Scott P. Kelly, Tatjana Lukic, Edward Nagy, Samantha K. Kurosky, Lynne Napatalung, Iltefat Hamzavi   +11 more
wiley   +1 more source

Bruton tyrosine kinase (Btk) in neutrophils is indispensable for initiating and maintaining skin inflammation in a model of pemphigoid diseases

British Journal of Pharmacology, Volume 183, Issue 10, Page 2446-2463, May 2026.
Background and Purpose Bruton tyrosine kinase (Btk) is essential for B cell function. Its role in myeloid cells is less understood. Greater insights into Btk significance in myeloid cells are needed to evaluate its potential as a therapeutic target during the effector phase of antibody‐induced autoimmune diseases, where inhibiting autoantibody ...
Henning Olbrich, Paul Schilf, Sripriya Murthy, Sina Gonther, Mareike Neumann, Christoph M. Hammers, Jasper N. Pruessmann, Christian D. Sadik   +7 more
wiley   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, Volume 183, Issue 9, Page 1779-1813, May 2026.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, Volume 116, Issue 5, Page 522-534, May 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes

Research
Background: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF).
Yukun Li, Xinmeng Liu, Rong Lin, Xiaodong Peng, Xuesi Wang, Fanchao Meng, Shuqi Jin, Wenhe Lv, Xiaoying Liu, Zhuohang Du, Songnan Wen, Rong Bai, Yanfei Ruan, Hao Zhou, Rongjun Zou, Ribo Tang, Nian Liu   +16 more
doaj   +1 more source